vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Vivid Seats Inc. (SEAT). Click either name above to swap in a different company.

Vivid Seats Inc. is the larger business by last-quarter revenue ($97.5M vs $62.1M, roughly 1.6× Cytek Biosciences, Inc.). Vivid Seats Inc. runs the higher net margin — 1212.8% vs -70.9%, a 1283.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -41.0%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-38.3M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -21.9%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Vivid Seats Inc. is an American online ticket market place and resale company. It is the official ticketing partner of numerous sports teams and media outlets including ESPN, United Airlines, the San Francisco 49ers and the Los Angeles Chargers. Its rewards program allows fans to earn points on purchases. Vivid Seats is a member of the Internet Association, which advocates for net neutrality.

CTKB vs SEAT — Head-to-Head

Bigger by revenue
SEAT
SEAT
1.6× larger
SEAT
$97.5M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+49.1% gap
CTKB
8.1%
-41.0%
SEAT
Higher net margin
SEAT
SEAT
1283.7% more per $
SEAT
1212.8%
-70.9%
CTKB
More free cash flow
CTKB
CTKB
$36.5M more FCF
CTKB
$-1.8M
$-38.3M
SEAT
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
-21.9%
SEAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
SEAT
SEAT
Revenue
$62.1M
$97.5M
Net Profit
$-44.1M
$1.2B
Gross Margin
52.9%
Operating Margin
-9.0%
Net Margin
-70.9%
1212.8%
Revenue YoY
8.1%
-41.0%
Net Profit YoY
-557.1%
12369.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
SEAT
SEAT
Q4 25
$62.1M
$97.5M
Q3 25
$52.3M
$104.8M
Q2 25
$45.6M
$114.5M
Q1 25
$41.5M
$133.7M
Q4 24
$57.5M
$165.2M
Q3 24
$51.5M
$152.7M
Q2 24
$46.6M
$170.0M
Q1 24
$44.9M
$160.0M
Net Profit
CTKB
CTKB
SEAT
SEAT
Q4 25
$-44.1M
$1.2B
Q3 25
$-5.5M
$-30.2M
Q2 25
$-5.6M
$-335.4M
Q1 25
$-11.4M
$-10.6M
Q4 24
$9.6M
$-9.6M
Q3 24
$941.0K
$10.6M
Q2 24
$-10.4M
$-437.0K
Q1 24
$-6.2M
$12.9M
Gross Margin
CTKB
CTKB
SEAT
SEAT
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
58.5%
Q3 24
56.3%
Q2 24
54.6%
Q1 24
51.3%
Operating Margin
CTKB
CTKB
SEAT
SEAT
Q4 25
-9.0%
Q3 25
-17.6%
Q2 25
-23.3%
Q1 25
-36.1%
Q4 24
5.2%
Q3 24
-8.2%
Q2 24
-18.3%
Q1 24
-23.9%
Net Margin
CTKB
CTKB
SEAT
SEAT
Q4 25
-70.9%
1212.8%
Q3 25
-10.5%
-28.9%
Q2 25
-12.2%
-293.0%
Q1 25
-27.5%
-7.9%
Q4 24
16.8%
-5.8%
Q3 24
1.8%
7.0%
Q2 24
-22.4%
-0.3%
Q1 24
-13.8%
8.0%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
SEAT
SEAT
Cash + ST InvestmentsLiquidity on hand
$90.9M
$102.7M
Total DebtLower is stronger
$16.5M
Stockholders' EquityBook value
$341.7M
$-85.1M
Total Assets
$461.5M
$636.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
SEAT
SEAT
Q4 25
$90.9M
$102.7M
Q3 25
$93.3M
$145.1M
Q2 25
$75.5M
$153.0M
Q1 25
$95.3M
$199.5M
Q4 24
$98.7M
$243.5M
Q3 24
$162.3M
$202.3M
Q2 24
$177.9M
$234.3M
Q1 24
$168.8M
$154.0M
Total Debt
CTKB
CTKB
SEAT
SEAT
Q4 25
$16.5M
Q3 25
$17.1M
Q2 25
$17.7M
Q1 25
$18.2M
Q4 24
$18.7M
Q3 24
$15.8M
Q2 24
$16.1M
Q1 24
$15.7M
Stockholders' Equity
CTKB
CTKB
SEAT
SEAT
Q4 25
$341.7M
$-85.1M
Q3 25
$378.6M
$272.2M
Q2 25
$377.6M
$217.3M
Q1 25
$379.6M
$380.7M
Q4 24
$395.7M
$261.1M
Q3 24
$385.5M
$329.4M
Q2 24
$389.1M
$155.8M
Q1 24
$392.6M
$139.6M
Total Assets
CTKB
CTKB
SEAT
SEAT
Q4 25
$461.5M
$636.9M
Q3 25
$494.9M
$1.1B
Q2 25
$493.3M
$1.1B
Q1 25
$482.6M
$1.6B
Q4 24
$499.5M
$1.6B
Q3 24
$491.2M
$1.6B
Q2 24
$483.7M
$1.7B
Q1 24
$492.1M
$1.6B
Debt / Equity
CTKB
CTKB
SEAT
SEAT
Q4 25
Q3 25
0.06×
Q2 25
0.08×
Q1 25
0.05×
Q4 24
0.07×
Q3 24
0.05×
Q2 24
0.10×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
SEAT
SEAT
Operating Cash FlowLast quarter
$-771.0K
$-38.2M
Free Cash FlowOCF − Capex
$-1.8M
$-38.3M
FCF MarginFCF / Revenue
-2.9%
-39.3%
Capex IntensityCapex / Revenue
1.6%
0.1%
Cash ConversionOCF / Net Profit
-0.03×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-93.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
SEAT
SEAT
Q4 25
$-771.0K
$-38.2M
Q3 25
$-3.9M
$512.0K
Q2 25
$108.0K
$-28.6M
Q1 25
$-125.0K
$-25.3M
Q4 24
$2.0M
$47.8M
Q3 24
$13.2M
$-19.2M
Q2 24
$6.2M
$-13.8M
Q1 24
$4.0M
$39.2M
Free Cash Flow
CTKB
CTKB
SEAT
SEAT
Q4 25
$-1.8M
$-38.3M
Q3 25
$-4.6M
$502.0K
Q2 25
$-1.5M
$-28.8M
Q1 25
$-974.0K
$-27.1M
Q4 24
$1.1M
$44.3M
Q3 24
$12.2M
$-19.6M
Q2 24
$5.2M
$-14.1M
Q1 24
$3.4M
$39.1M
FCF Margin
CTKB
CTKB
SEAT
SEAT
Q4 25
-2.9%
-39.3%
Q3 25
-8.7%
0.5%
Q2 25
-3.2%
-25.2%
Q1 25
-2.3%
-20.3%
Q4 24
1.9%
26.8%
Q3 24
23.7%
-12.8%
Q2 24
11.0%
-8.3%
Q1 24
7.6%
24.4%
Capex Intensity
CTKB
CTKB
SEAT
SEAT
Q4 25
1.6%
0.1%
Q3 25
1.3%
0.0%
Q2 25
3.5%
0.2%
Q1 25
2.0%
1.4%
Q4 24
1.6%
2.1%
Q3 24
2.0%
0.3%
Q2 24
2.3%
0.2%
Q1 24
1.3%
0.1%
Cash Conversion
CTKB
CTKB
SEAT
SEAT
Q4 25
-0.03×
Q3 25
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
14.05×
-1.81×
Q2 24
Q1 24
3.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

SEAT
SEAT

Concerts$34.3M35%
Resale$29.3M30%
Theater$24.4M25%
Private Label$7.2M7%
Other$2.2M2%

Related Comparisons